Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 19,909 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 19,909 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $11.02, for a total value of $219,397.18. Following the completion of the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $2,600,565.72. This trade represents a 7.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Stock Performance

Personalis stock traded up $0.42 during midday trading on Friday, reaching $11.40. The company’s stock had a trading volume of 4,471,474 shares, compared to its average volume of 2,505,722. The firm has a market capitalization of $1.19 billion, a PE ratio of -11.18 and a beta of 1.96. Personalis, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $11.85. The stock’s 50 day simple moving average is $6.86 and its 200 day simple moving average is $8.10.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Equities analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PSNL. Caitong International Asset Management Co. Ltd grew its holdings in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. Deutsche Bank AG grew its holdings in shares of Personalis by 4.5% during the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after purchasing an additional 1,655 shares during the period. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the period. Howland Capital Management LLC grew its holdings in shares of Personalis by 0.9% during the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after purchasing an additional 2,500 shares during the period. Finally, Intech Investment Management LLC grew its holdings in shares of Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares during the period. Institutional investors and hedge funds own 61.91% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PSNL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Morgan Stanley cut their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, Needham & Company LLC lifted their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Personalis currently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.